ストックスクリーナーアプリを入手
4.81
0.42%
0.02
アフターアワーズ：
4.81
前日終値:
$4.79
開ける：
$4.8
24時間の取引高:
25,787
Relative Volume:
0.54
時価総額：
$12.06M
収益：
-
当期純損益:
$-13.24M
株価収益率:
-0.72
EPS:
-6.6801
ネットキャッシュフロー:
$-12.61M
1週間 パフォーマンス:
-0.82%
1か月 パフォーマンス:
-35.00%
6か月 パフォーマンス:
-65.80%
1年 パフォーマンス:
-70.53%
1日の値動き範囲:
$4.70
$4.90
1週間の範囲:
$4.51
$5.1494
52週間の値動き範囲:
$4.21
$17.50
Cadrenal Therapeutics Inc Stock (CVKD) Company Profile
Compare CVKD vs VRTX, REGN, ARGX, ALNY, ONC
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
CVKD
Cadrenal Therapeutics Inc
|
4.81 | 12.01M | 0 | -13.24M | -12.61M | -6.6801 |
VRTX
Vertex Pharmaceuticals Inc
|
441.70 | 113.01B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
753.93 | 79.87B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
840.87 | 51.51B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
333.39 | 45.29B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
319.94 | 34.41B | 5.36B | 287.73M | 924.18M | 2.5229 |
Cadrenal Therapeutics Inc Stock (CVKD) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2023-12-18 | 開始されました | Noble Capital Markets | Outperform |
Cadrenal Therapeutics Inc (CVKD) 最新ニュース
Retail Surge: What is the next catalyst for Cadrenal Therapeutics IncWeekly Stock Recap & Reliable Price Action Trade Plans - baoquankhu1.vn
FDA Review Uncertainty Puts Cadrenal Therapeutics’ CAD-1005 Phase 3 Timeline and Costs at Risk - TipRanks
Earnings Beat: Can Cadrenal Therapeutics Inc stock double in the next year - baoquankhu1.vn
Cadrenal Therapeutics Reports Fourth Quarter 2025 Financial Results; Provides Corporate Update on CAD-1005 Program for HIT Following End-of-Phase 2 FDA Meeting - ADVFN
CVKD: Results Show 12-LOX Inhibition Targets Inflammation from Obesity and Type 2 Diabetes - Yahoo Finance
CVKD: Analyst Maintains Buy Rating, But Lowers Price Target | CV - GuruFocus
Cadrenal Therapeutics price target lowered to $13 from $32 at H.C. Wainwright - TipRanks
CVKD Technical Analysis | Trend, Signals & Chart Patterns | CADRENAL THERAPEUTICS INC (NASDAQ:CVKD) - ChartMill
Cadrenal Therapeutics, Inc. (CVKD) stock price, news, quote and history - Yahoo Finance UK
Noble Financial Remains a Buy on Cadrenal Therapeutics, Inc. (CVKD) - The Globe and Mail
Cadrenal Therapeutics Announces Warrant Inducement Agreement and Issuance of New Warrants – Form 8-K Filing - Minichart
Cadrenal Therapeutics Enters Warrant Inducement Financing Agreement - TipRanks
Cadrenal Therapeutics Raises $2.5 Million via Warrant Exercise, Issues New $4.50 Warrants - TradingView — Track All Markets
Warrant exercise gives Cadrenal (NASDAQ: CVKD) $2.5M cash - Stock Titan
Cadrenal Therapeutics (NASDAQ: CVKD) amends warrants; registers 590,001 shares - Stock Titan
Cadrenal Therapeutics Reports Positive Phase 2 HIT Results and FDA Progress for CAD-1005, Announces Q4 2025 Financials - Minichart
Cadrenal reports Q4 loss, completes FDA meeting on HIT therapy By Investing.com - Investing.com South Africa
Cadrenal Therapeutics Advances CAD-1005 for HIT Treatment: Clinical Progress, Market Opportunity, and Regulatory Insights - Minichart
Cadrenal Therapeutics 2025 10-K: Net loss $13.24M, EPS $(6.64) - TradingView — Track All Markets
Cadrenal Therapeutics (NASDAQ: CVKD) pivots to CAD-1005 and expands clotting disorder pipeline - Stock Titan
Cadrenal Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025 - marketscreener.com
Cadrenal reports Q4 loss, completes FDA meeting on HIT therapy - Investing.com
Cadrenal Therapeutics (NASDAQ: CVKD) widens 2025 loss, advances CAD-1005 toward Phase 3 - Stock Titan
Dividend Watch: Is Cadrenal Therapeutics Inc a strong growth stockFed Meeting & Free Community Supported Trade Ideas - baoquankhu1.vn
Cadrenal Therapeutics, Inc. (CVKD) Eps Diluted (TTM) - zacks.com
CVKD Should I Buy - Intellectia AI
12 Health Care Stocks Moving In Wednesday's Intraday Session - Benzinga
Technical Reactions to CVKD Trends in Macro Strategies - Stock Traders Daily
Fed Meeting: What is Cadrenal Therapeutics Incs valuation compared to sectorGold Moves & Fast Moving Trade Plans - baoquankhu1.vn
Buy Signal: Will Cadrenal Therapeutics Inc outperform its industry peersPortfolio Performance Summary & AI Forecasted Stock Moves - baoquankhu1.vn
OTC Markets Hosts Virtual Investor Presentation with Quang Pham, Chairman and CEO of Cadrenal Therapeutics, and David Bautz, PhD, Senior Analyst at Zacks SCR - Zacks Small Cap Research
Trading Action: Is Cadrenal Therapeutics Inc stock overvalued or fairly pricedEarnings Overview Summary & Verified Short-Term Plans - baoquankhu1.vn
Cadrenal Therapeutics Highlights CAD-1005 In-License, Maps Phase III Path for HIT at Investor Forum - Defense World
CVKD SEC FilingsCadrenal Therape 10-K, 10-Q, 8-K Forms - Stock Titan
Cadrenal Therapeutics, Inc. (CVKD) stock: surges on breakthrough 12-LOX diabetes research - parameter.io
Cadrenal Therapeutics Inc. (CVKD) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
Trading the Move, Not the Narrative: (CVKD) Edition - Stock Traders Daily
Cadrenal Therapeutics Highlights Research Supporting 12-LOX Inhibition in Reducing Inflammation in Obesity and Type 2 Diabetes - Sahm
CVKD: CAD-1005 moves to phase III for HIT, aiming to address a critical unmet need with strong safety data - tradingview.com
CVKD: CAD-1005 advances to phase III for HIT, targeting a major unmet need with strong regulatory support - TradingView
Cadrenal Highlights CAD-1005 Preclinical Data in Metabolic Disease - TipRanks
Cadrenal Therapeutics (CVKD) spotlights CAD-1005 12-LOX data in obesity, diabetes and HIT - Stock Titan
Trend Recap: What is Cadrenal Therapeutics Incs valuation compared to sector2026 Top Gainers & Expert-Curated Trade Recommendations - baoquankhu1.vn
Cadrenal Therapeutics Inc expected to post a loss of $1.16 a shareEarnings Preview - TradingView
CVKD Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
CVKD Stock Price, Quote & Chart | CADRENAL THERAPEUTICS INC (NASDAQ:CVKD) - ChartMill
CVKD Earnings History & Surprises | EPS & Revenue Results | CADRENAL THERAPEUTICS INC (NASDAQ:CVKD) - ChartMill
Cadrenal Therapeutics (CVKD) Projected to Post Quarterly Earnings on Thursday - Defense World
CVKDCadrenal Therapeutics Highlights Recent 12-LOX Inhibitor Platform Expansion - ADVFN Ltd
Cadrenal schedules FDA meeting for HIT drug CAD-1005 - Investing.com India
Cadrenal Therapeutics Highlights Recent 12-LOX Inhibitor Platform Expansion - GlobeNewswire
Cadrenal Therapeutics Inc (CVKD) 財務データ
収益
当期純利益
現金流量
EPS
2.69%
0.25%
大文字化:
|
ボリューム (24 時間):